FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction

Why it matters locally: The approval of an oral PCSK9 inhibitor provides a new treatment option that could significantly impact the health of Mississippians, particularly given the state's higher rates of cardiovascular disease and related risk factors such as high cholesterol. Access to this new medication could improve cholesterol management for patients across the state.

WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.